CRVS (STOCKS)
Corvus Pharmaceuticals, Inc.
$12.220000
+0.290000 (+2.43%)
Prev close: $11.930000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard A. Miller
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,003.20M
- Employees
- 31
- P/E (TTM)
- -22.62
- P/B (TTM)
- 4.17
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.15 | $-0.15 | -0.0043 | -2.95% |
|
Dec 2025 (Q4)
|
$-0.15 | $-0.13 | -0.0181 | -13.72% |
|
Sep 2025 (Q3)
|
$-0.12 | $-0.14 | +0.0161 | +11.83% |
|
Jun 2025 (Q2)
|
$-0.10 | $-0.14 | +0.0426 | +29.87% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $47.93M |
| Depreciation and Amortization | $107.00K |
| Research and Development | $37.44M |
| Other Operating Expenses | $10.38M |
| Operating Income/Loss | -$47.93M |
| Income/Loss Before Equity Method Investments | -$42.15M |
| Income/Loss From Continuing Operations After Tax | -$42.54M |
| Income/Loss From Continuing Operations Before Tax | -$42.15M |
| Income/Loss From Equity Method Investments | -$2.02M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$44.17M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$44.17M |
| Net Income/Loss Available To Common Stockholders, Basic | -$44.17M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.52 |
| Diluted Earnings Per Share | -$0.52 |
| Basic Average Shares | 251,953,983 |
| Diluted Average Shares | 251,694,702 |
| Assets | $253.20M |
| Current Assets | $239.95M |
| Cash | $236.70M |
| Other Current Assets | $3.25M |
| Noncurrent Assets | $13.25M |
| Fixed Assets | $282.00K |
| Other Non-current Assets | $12.97M |
| Liabilities | $12.52M |
| Current Liabilities | $12.11M |
| Accounts Payable | $4.70M |
| Wages | $1.38M |
| Other Current Liabilities | $6.03M |
| Noncurrent Liabilities | $406.00K |
| Equity | $240.68M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $240.68M |
| Liabilities And Equity | $253.20M |
| Net Cash Flow From Operating Activities | -$34.91M |
| Net Cash Flow From Operating Activities, Continuing | -$34.91M |
| Net Cash Flow From Investing Activities | -$156.89M |
| Net Cash Flow From Investing Activities, Continuing | -$156.89M |
| Net Cash Flow From Financing Activities | $226.90M |
| Net Cash Flow From Financing Activities, Continuing | $226.90M |
| Net Cash Flow | $35.10M |
| Net Cash Flow, Continuing | $35.10M |
| Comprehensive Income/Loss | -$44.15M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$44.04M |
| Other Comprehensive Income/Loss | -$10.14M |